Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 21.68% is 68% above its 5-year average of 12.89%, near the high end of its 5-year range (8.19%–21.68%).
As of the fiscal period ended Wednesday, December 31, 2025. 36.35% above its 12-month average of 15.90%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
21.68%
RETURN ON ASSETS (ROA) AVG TTM
15.90%
RETURN ON ASSETS (ROA) AVG 3Y
13.15%
RETURN ON ASSETS (ROA) AVG 5Y
12.89%
RETURN ON ASSETS (ROA) AVG 10Y
10.84%
RETURN ON ASSETS (ROA) AVG 15Y
11.27%
RETURN ON ASSETS (ROA) AVG 20Y
11.36%
CURRENT VS TTM AVG
+36.35%
CURRENT VS 3Y AVG
+64.84%
CURRENT VS 5Y AVG
+68.21%
CURRENT VS 10Y AVG
+100.02%
CURRENT VS 15Y AVG
+92.43%
CURRENT VS 20Y AVG
+90.83%
SECTOR MEDIAN · HEALTHCARE
4.97%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+336.22%
vs the sector median at left
Eli Lilly and Company
Market Cap
$1.08T
Return on Assets (ROA)
21.68%
TTM Avg
15.90%
3Y Avg
13.15%
5Y Avg
12.89%
Market Cap
$617.78B
Return on Assets (ROA)
10.46%
TTM Avg
10.63%
3Y Avg
12.96%
5Y Avg
11.95%
Market Cap
$443.24B
Return on Assets (ROA)
2.67%
TTM Avg
3.16%
3Y Avg
4.61%
5Y Avg
4.90%
Market Cap
$376.34B
Return on Assets (ROA)
4.56%
TTM Avg
4.36%
3Y Avg
6.27%
5Y Avg
6.84%
Market Cap
$321.62B
Return on Assets (ROA)
6.94%
TTM Avg
13.98%
3Y Avg
10.40%
5Y Avg
10.28%
Market Cap
$213.42B
Return on Assets (ROA)
6.17%
TTM Avg
6.31%
3Y Avg
6.46%
5Y Avg
7.20%
Market Cap
$209.19B
Return on Assets (ROA)
22.06%
TTM Avg
20.27%
3Y Avg
22.54%
5Y Avg
48.60%
Market Cap
$184.11B
Return on Assets (ROA)
4.97%
TTM Avg
11.99%
3Y Avg
10.28%
5Y Avg
9.45%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eli Lilly and Company (LLY) | $1.08T | 21.68% | 15.90% | 13.15% | 12.89% |
| Johnson & Johnson (JNJ)vs › | $617.78B | 10.46% | 10.63% | 12.96% | 11.95% |
| AbbVie Inc. (ABBV)vs › | $443.24B | 2.67% | 3.16% | 4.61% | 4.90% |
| UnitedHealth Group Incorporated (UNH)vs › | $376.34B | 4.56% | 4.36% | 6.27% | 6.84% |
| Merck & Co., Inc. (MRK)vs › | $321.62B | 6.94% | 13.98% | 10.40% | 10.28% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $213.42B | 6.17% | 6.31% | 6.46% | 7.20% |
| Novo Nordisk A/S (NVO)vs › | $209.19B | 22.06% | 20.27% | 22.54% | 48.60% |
| Amgen Inc. (AMGN)vs › | $207.87B | 8.43% | 6.48% | 7.48% | 8.52% |
| Abbott Laboratories (ABT)vs › | $184.11B | 4.97% | 11.99% | 10.28% | 9.45% |
| Gilead Sciences, Inc. (GILD)vs › | $161.66B | 16.38% | 7.62% | 7.90% | 6.83% |
ROA
21.7%
ROE
81.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 18.35% |
| 2024-12-31 | 13.45% |
| 2023-12-31 | 8.19% |
| 2022-12-31 | 12.62% |
| 2021-12-31 | 11.44% |
| 2020-12-31 | 13.28% |
| 2019-12-31 | 21.17% |
| 2018-12-31 | 7.36% |
| 2017-12-31 | -0.45% |
| 2016-12-31 | 7.05% |
| 2015-12-31 | 6.77% |
| 2014-12-31 | 6.58% |
| 2013-12-31 | 13.29% |
| 2012-12-31 | 11.89% |
| 2011-12-31 | 12.92% |
| 2010-12-31 | 16.35% |
| 2009-12-31 | 15.76% |
| 2008-12-31 | -7.09% |
| 2007-12-31 | 11.02% |
| 2006-12-31 | 12.13% |
| 2005-12-31 | 8.05% |
| 2004-12-31 | 7.28% |
| 2003-12-31 | 11.81% |
| 2002-12-31 | 14.22% |
| 2001-12-31 | 16.92% |
| 2000-12-31 | 20.81% |
| 1999-12-31 | 21.22% |
| 1998-12-31 | 16.66% |
| 1997-12-31 | -3.06% |
| 1996-12-31 | 10.65% |
